IDEAYA Biosciences (IDYA) AI Stock Analysis

• Market Cap: $2.18B
• Dividend Yield: N/A
• Average Volume (3M): 1.15M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.54
• Revenue Growth: -41.48%
• EPS Growth: -73.55%
• Country: US
• Employees: 131
• Sector: Healthcare
• Sector Strength: 51
• Industry: Biotechnology
• EPS (TTM): -0.88
• Shares Outstanding: 87,643,684
• 10 Day Avg. Volume: 1,530,230
• 30 Day Avg. Volume: 1,148,647
• PEG Ratio: -0.11
• Price to Book (P/B): 1.98
• Price to Sales (P/S): 299.87
• P/FCF Ratio: -8.35
• Enterprise Value/Market Cap: 0.56
• Enterprise Value/Revenue: 173.79
• Enterprise Value/Gross Profit: 231.28
• Enterprise Value/Ebitda: -3.40
• 1Y Price Target: $46.67
• Price Target Upside: 87.20% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 14

• Rating: 51 Neutral
• Price Target: $25.00 ▲(0.28% Upside)

The overall stock score reflects significant financial challenges, with declining revenues and consistent net losses being the most impactful factors. While technical analysis shows positive trends, the negative P/E ratio and lack of dividend yield weigh heavily on the valuation.

Positive Factors

Promising Clinical Trial Results

The promising clinical trial results for IDE397 in combination with Trodelvy indicate potential advancements in treatment for urothelial cancer, enhancing IDEAYA's competitive position in oncology and supporting long-term growth prospects.

Strategic Licensing Agreement

The licensing agreement with Servier provides significant upfront payment and potential milestone payments, extending IDEAYA's cash runway and supporting financial stability, which is crucial for sustained R&D and operational growth.

Innovative Oncology Pipeline

The development of IDE849 and other innovative therapies in IDEAYA's pipeline highlights its focus on precision medicine, potentially leading to breakthrough treatments and strengthening its market position in biotechnology.

Negative Factors

Declining Revenue

The substantial decline in revenue indicates challenges in monetizing its pipeline, which could hinder long-term financial sustainability and necessitate strategic adjustments to improve revenue streams.

Consistent Net Losses

Persistent net losses reflect ongoing operational challenges, potentially limiting IDEAYA's ability to invest in R&D and expand its pipeline, which could affect its competitive edge in the long run.

Negative Cash Flow

Negative cash flow highlights the company's reliance on external financing, which may constrain its financial flexibility and ability to sustain long-term growth without strategic financial management improvements.

IDEAYA Biosciences Business Overview & Revenue Model

Company Description

IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's lead product candidates include IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase I clinical trial for patients with solid tumors having methylthioadenosine phosphorylase deletions; and IDE196, a protein kinase C inhibitor that is in Phase I/II clinical trial for genetically defined cancers having GNAQ or GNA11 gene mutations. Its preclinical pipeline includes various synthetic lethality programs targeting PARG inhibitor in tumors for patients having tumors with a defined biomarker based on genetic mutations and/or molecular signatures; Pol Theta inhibitors in tumors with BRCA or other homologous recombination deficiency mutations; and WRN inhibitors in tumors with high microsatellite instability. The company has a research collaboration agreement with Cancer Research UK and the University of Manchester to develop small molecule inhibitors of Poly (ADP-ribose) glycohydrolase; and a clinical trial collaboration and supply agreement with Pfizer Inc. for Phase I/II study in metastatic uveal melanoma, skin melanoma, and other solid tumors, as well as a strategic partnership with GlaxoSmithKline plc. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

How the Company Makes Money

IDEAYA Biosciences generates revenue through a combination of its own product development efforts and strategic partnerships. The company primarily earns money by advancing its pipeline of drug candidates through various stages of clinical trials, leading to potential commercialization. Additionally, IDEAYA enters into collaborations and licensing agreements with larger pharmaceutical companies, which can provide upfront payments, milestone payments based on development progress, and royalties on future sales. These partnerships not only offer financial support but also access to resources and expertise necessary for efficient drug development. The company may also receive funding through grants and investments to support its research initiatives.

IDEAYA Biosciences Financial Statement Overview

Summary

IDEAYA Biosciences is experiencing financial difficulties with declining revenues and consistent net losses. Although it has a strong equity position, the lack of profitability and negative cash flows are significant risks.

Income Statement

The company has seen a significant decline in revenue over the past year, with a negative growth rate of 70%. Gross profit margin remains at 100% due to no cost of goods sold reported. However, high negative net profit, EBIT, and EBITDA margins reflect operational challenges and lack of profitability.

Balance Sheet

IDEAYA Biosciences maintains a strong equity base, with an equity ratio of 94%. The debt-to-equity ratio is low, indicating minimal leverage, but return on equity is negative due to net losses, highlighting profitability challenges.

Cash Flow

Operating cash flow and free cash flow are both negative, indicating cash burn from operations. However, the company has managed substantial financing activities, improving cash reserves significantly, albeit not enough to cover the free cash flow deficit.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	7.00M	7.00M	23.39M	50.93M	27.94M	19.54M
Gross Profit	5.26M	7.00M	19.38M	48.83M	26.22M	-20.16M
EBITDA	-357.95M	-326.98M	-130.42M	-60.40M	-48.54M	-33.96M
Net Income	-306.31M	-274.48M	-112.96M	-54.81M	-47.53M	-32.27M
Balance Sheet
Total Assets	1.10B	1.12B	649.32M	387.97M	381.35M	298.27M
Cash, Cash Equivalents and Short-Term Investments	692.51M	676.32M	525.11M	373.15M	368.06M	283.58M
Total Debt	25.97M	19.17M	2.87M	3.48M	5.18M	6.72M
Total Liabilities	76.51M	64.94M	28.23M	387.97M	381.35M	298.27M
Stockholders Equity	1.02B	1.06B	621.09M	349.45M	301.51M	198.27M
Cash Flow
Free Cash Flow	-267.98M	-251.44M	-117.59M	-90.62M	-58.42M	54.97M
Operating Cash Flow	-264.11M	-247.58M	-115.22M	-87.17M	-55.78M	55.46M
Investing Cash Flow	-68.77M	-502.56M	-158.46M	-33.40M	-69.67M	-146.24M
Financing Cash Flow	354.58M	677.55M	362.72M	97.17M	145.45M	128.75M

IDEAYA Biosciences Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 24.93
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IDYA, the sentiment is Positive. The current price of 24.93 is above the 20-day moving average (MA) of 24.88, above the 50-day MA of 23.84, and above the 200-day MA of 21.97, indicating a bullish trend. The MACD of 0.34 indicates Positive momentum. The RSI at 51.99 is Neutral, neither overbought nor oversold. The STOCH value of 35.05 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IDYA.

IDEAYA Biosciences Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
IMCR	68 Neutral	$1.83B	―	-5.38%	―	26.90%	62.72%
CGON	65 Neutral	$2.53B	―	-20.95%	―	―	―
KYMR	57 Neutral	$3.30B	―	-33.26%	―	-49.51%	-44.09%
Sector *	51 Neutral	$8.02B	-0.39	-43.38%	2.20%	22.34%	-2.13%
IDYA	51 Neutral	$2.18B	―	-35.09%	―	-41.48%	-73.55%
BEAM	50 Neutral	$2.01B	―	-41.94%	―	-82.90%	-155.64%
ETNB	42 Neutral	$1.26B	―	-86.86%	―	―	-82.75%